Featured in NEJM Journal Watch: Incretin-Based Diabetes Drugs Aren't Associated with Excess Risk for Acute Pancreatitis (FREE)
Extract
Although not the final word, results of two large studies in BMJ should be reassuring for patients taking exenatide (Byetta) and sitagliptin (Januvia... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 8, 2014 Category: Primary Care Source Type: news
Exenatide has potential as disease modifying agent in Parkinson's disease
A follow-up study of patients with Parkinson's disease (PD) who participated in an earlier 'proof of concept' clinical trial using exenatide showed that improvements persisted 12 months after discontinuing exenatide therapy. These data provide strong encouragement for the further study of this drug in patients with PD, report researchers. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 6, 2014 Category: Science Source Type: news
Exenatide's Effect on Beta-cell Function in New Onset T2DMExenatide's Effect on Beta-cell Function in New Onset T2DM
Does daily GLP-1 receptor agonist use improve beta-cell function? Clinical Endocrinology (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 3, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology Journal Article Source Type: news
AstraZeneca obtains FDA approval for Bydureon Pen to treat type 2 diabetes
AstraZeneca has received approval from the US Food and Drug Administration (FDA) for its Bydureon Pen (exenatide extended-release for injectable suspension) 2mg as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 dia… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 5, 2014 Category: Pharmaceuticals Source Type: news
FDA Approves Pen Form of Extended-Release ExenatideFDA Approves Pen Form of Extended-Release Exenatide
A new product contains the same formulation and dosing of current extended-release exenatide but eliminates the need for filling a syringe. FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 3, 2014 Category: Consumer Health News Tags: Medscape Today News Alert Source Type: news
FDA Approves Bydureon Pen
(MedPage Today) -- The FDA has approved a new means of delivery for weekly exenatide (Bydureon) - a pen formulation - for patients with type 2 diabetes. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 3, 2014 Category: Cardiology Source Type: news
Incretin-Targeting Diabetic Drugs: FDA & EMA See No Apparent Pancreatic Harms (FREE)
By Joe Elia
Drugs targeting the insulin-releasing effects of the hormone incretin, such as exenatide (Byetta) and sitagliptin (Januvia), cause no apparent increase in pancreatic side effects, according to a … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 28, 2014 Category: Primary Care Source Type: news
Byetta Lawsuit Plaintiff Withdraws Motion Seeking Consolidation of...
The Firm is evaluating Byetta lawsuits on behalf of patients who allegedly developed pancreatic cancer, pancreatitis, or thyroid cancer due to their use of the Type 2 diabetes medication.(PRWeb February 22, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb11608217.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 22, 2014 Category: Pharmaceuticals Source Type: news
Byetta Lawsuit Update: Court Considering Case Management Proposals in...
The Firm is investigating Byetta lawsuits on behalf of individuals who developed pancreatic cancer, thyroid cancer or pancreatitis, allegedly due to their use of the Type 2 diabetes medication.(PRWeb February 17, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb11587413.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 17, 2014 Category: Pharmaceuticals Source Type: news
As Byetta Lawsuits Move Forward, Bernstein Liebhard LLP Notes New FDA...
The Firm is evaluating Byetta lawsuits and other legal claims on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis, and thyroid cancer due their use of incretin mimetic...(PRWeb February 13, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb11583185.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 14, 2014 Category: Pharmaceuticals Source Type: news
Byetta Lawsuits Move Forward, as Federal and State Incretin Mimetics...
The Firm is investigating Byetta lawsuits that allege an association between the use of Byetta and pancreatic cancer, as well as pancreatitis and thyroid cancer.(PRWeb January 25, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb11521828.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 25, 2014 Category: Pharmaceuticals Source Type: news
Byetta Lawsuit News: More Than 260 Product Liability Claims Now...
The Firm is investigating Byetta lawsuits on behalf of individuals who developed pancreatic cancer, pancreatitis, or thyroid cancer, allegedly due to their use of Byetta.(PRWeb January 16, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb11496700.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 17, 2014 Category: Pharmaceuticals Source Type: news
Bernstein Liebhard LLP Notes Progress in Federal Byetta Lawsuit...
The attorneys at Bernstein Liebhard LLP are actively investigating potential Byetta lawsuit claims alleging pancreatic cancer, pancreatitis and thyroid cancer caused by the diabetes medication.(PRWeb December 22, 2013)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb11442741.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 23, 2013 Category: Pharmaceuticals Source Type: news
Byetta Lawsuit News: Bernstein Liebhard LLP Notes Scheduling of...
The Firm is investigating potential Byetta lawsuits on behalf of alleged victims of Byetta and pancreatic cancer, pancreatitis and thyroid cancer.(PRWeb December 03, 2013)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb11388186.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 4, 2013 Category: Pharmaceuticals Source Type: news
Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Issuance...
The Firm is currently investigating Byetta lawsuits that allege an association between use of Byetta and pancreatic cancer, as well as pancreatitis and thyroid cancer.(PRWeb November 16, 2013)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb11339864.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 19, 2013 Category: Pharmaceuticals Source Type: news
